Effects of tamoxifen on hepatic fat content and the development of hepatic steatosis in patients with breast cancer: High frequency of involvement and rapid reversal after completion of tamoxifen therapy

American Journal of Roentgenology

Volumn 180, Issue 1, 2003, Pages 129-134

  Nishino, Mizuki ^a   Hayakawa, Katsumi ^a   Nakamura, Yoshiaki ^a   Morimoto, Taisuke ^a   Mukaihara, Sumio ^a  

^a KYOTO CITY HOSPITAL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

TAMOXIFEN; UFT;

ADULT; AGED; ARTICLE; BREAST CANCER; CALCULATION; CANCER COMBINATION CHEMOTHERAPY; COMPUTER ASSISTED TOMOGRAPHY; CONVALESCENCE; DIAGNOSTIC IMAGING; DIFFERENTIAL DIAGNOSIS; DRUG INDUCED DISEASE; FAT CONTENT; FATTY LIVER; HUMAN; IMAGE ANALYSIS; LIVER DYSFUNCTION; LIVER METASTASIS; PRIORITY JOURNAL; RETROSPECTIVE STUDY;

EID: 0037216370     PISSN: 0361803X     EISSN: None     Source Type: Journal    
DOI: 10.2214/ajr.180.1.1800129     Document Type: Article

References (16)

1. Adjuvant therapy for breast cancer. NIH consensus statement. 2000. NIH Web site. Available at http://consensus.nih.gov. Accessed September-October 2001
2. [No authors listed] Tamoxifen for early breast cancer: An overview of the randomized trials-Early Breast Cancer Trialists' Collaborative Group. Lancet 1998;351:1451-1467
3. Pratt DS, Knox TA, Erban J. Tamoxifen-induced steatohepatitis. (letter) Ann Intern Med 1995;123:236
4. Van Hoof M, Rahier J, Horsmans Y. Tamoxifen-induced steatohepatitis. (letter) Ann Intern Med 1996; 124:855
5. Ogawa Y, Murata Y, Nishioka A, Inomata T, Yoshida S. Tamoxifen-induced fatty liver in patients with breast cancer. (letter) Lancet 1998;351:725
6. Oien K, Moffat D, Curry GW, et al. Cirrhosis with steatohepatitis after adjuvant tamoxifen. Lancet 1999;353:36-37
7. Cai Q, Bensen M, Greene R, Krichner J. Tamoxifen-induced transient multifocal hepatic fatty infiltration. Am J Gastroenterol 2000;95:277-279
8. Murata Y, Ogawa Y, Saibara T, et al. Unrecognized hepatic steatosis and non-alcoholic steatohepatitis in adjuvant tamoxifen for breast cancer patients. Oncol Rep 2000;7:1299-1304
9. Ricci C, Longo R, Gioulis E, et al. Noninvasive in vivo quantitative assessment of fat content in human liver. J Hepatol 1997;27:108-113
10. Nemoto Y, Toda K, Ono M, et. al. Altered expression of fatty acid-metabolizing enzymes in aromatase-deficient mice. J Clin Invest 2000;105:1819-1825
11. Kawamoto S, Soyer P, Fishman EK, Bluemke DA. Nonneoplastic liver disease: Evaluation with CT and MR imaging. RadioGraphics 1998;18:827-848
12. Nomura F, Ohnishi K, Ochiai T, Okuda K. Obesity-related nonalcoholic fatty liver: CT features and follow-up studies after low-calorie diet. Radiology 1987;162:845-847
13. Gates GF, Dore EK. Streamline flow in the human portal vein. J Nucl Med 1973;14:79-83
14. Norum J. 5-fluorouracil/levamisole induced intrahepatic fat infiltration imitating liver metastasis. Acta Oncol 1995;34:971-972
15. Sorensen P, Edal AL, Madsen EL, Fenger C, Poulsen MR, Petersen OF. Reversible hepatic steatosis in patients treated with interferon alpha-2a and 5-fluorouracil. Cancer 1995;75:2592-2596
16. Peppercorn PD, Reznek RH, Wilson P, Selvin ML, Gupta RK. Demonstration of hepatic steatosis by computerized tomography in patients receiving 5-fluorouracil-based therapy for advanced colorectal cancer. Br J Cancer 1998;77:2008-2011